Open Access. Powered by Scholars. Published by Universities.®

Immunoprophylaxis and Therapy Commons

Open Access. Powered by Scholars. Published by Universities.®

252 Full-Text Articles 1,135 Authors 38,608 Downloads 33 Institutions

All Articles in Immunoprophylaxis and Therapy

Faceted Search

252 full-text articles. Page 1 of 13.

Evaluation Of The Humoral/Fc-Mediated Immune Responses To An Adenovirus-26 Viral Vector/Gp140 Subunit Combined Vaccine Regimen As A Prophylactic Hiv-1, Nathan E. Adam 2022 Cedarville University

Evaluation Of The Humoral/Fc-Mediated Immune Responses To An Adenovirus-26 Viral Vector/Gp140 Subunit Combined Vaccine Regimen As A Prophylactic Hiv-1, Nathan E. Adam

Channels: Where Disciplines Meet

Background and Introduction: HIV is one of the most problematic pandemics to date, currently infecting upwards of 38 million people worldwide (“The Global HIV/AIDS Epidemic,” 2020). Although infection and mortality rates have generally decreased, current prophylactic (preventive) measures against HIV-1 acquisition have shown major weaknesses that could be remedied with a vaccine (Pitisuttuthum & Marovich, 2020). Manufacturing an effective, prophylactic HIV-1 vaccine, however, is not without challenges - namely design/selection of vaccine-delivered immunogens (antigens) and elicitation of proper immune responses to HIV-1 antigens (Ng’uni et al., 2020). Fortunately, despite past, unsuccessful research, studies within the past 10-15 years have begun to elucidate immune correlates of protection against HIV-1 acquisition, specifically IgG1/IgG3 antibody (Ab) production, as well as non-neutralizing, Fc-Mediated effector functions (Rerks-Ngarm et al., 2009). Excitingly, studies released in the last 3 years, which use Adenovirus serotype-26 (Ad26) vector (Custers et al., 2020) show promising signs that an effective HIV-1 vaccine could become a reality (Baden et al., 2020; Barouch et al., 2018). Thus, for this presentation, I hope to show that Johnson & Johnson’s two new Ad26-based vaccines (combined with booster vaccines) sufficiently elicit key immune correlates of protection to warrant an Ad26 vector-based regimen’s testing past Phase 1/2a clinical trials. Results ...


Determinants Of Precocious B-Cell Aging In European Adolescents Living With Perinatally Acquired Hiv-1 After Over 10 Years Of Suppressive Therapy [Preprint], Alessandra Ruggiero, Katherine Luzuriaga, Paolo Palma 2021 University of Verona

Determinants Of Precocious B-Cell Aging In European Adolescents Living With Perinatally Acquired Hiv-1 After Over 10 Years Of Suppressive Therapy [Preprint], Alessandra Ruggiero, Katherine Luzuriaga, Paolo Palma

UMass Chan Medical School Faculty Publications

HIV infection results in a state of chronic immune activation leading to premature immune aging, B-cells dysfunction, that persists despite prolonged virological suppression. In this scenario, adolescence living with perinatally acquired HIV (PHIV), deserve a peculiar attention since potentially exposed for their entire life to chronic immune activation. Here we identified determinants of precocious aging B cells in 40 PHIV undergoing suppressive antiretroviral therapy (ART) for median 13.5 years. All individuals started ART by 2nd year of life and achieved virus suppression within the 1st year of ART, with majority of patient maintaining suppression until analysis and 5/40 ...


Severe Immune Thrombocytopenic Purpura After Sars-Cov-2 Vaccine, Katherine M. Cooper, Bradley A. Switzer 2021 University of Massachusetts Medical School

Severe Immune Thrombocytopenic Purpura After Sars-Cov-2 Vaccine, Katherine M. Cooper, Bradley A. Switzer

COVID-19 Publications by UMass Chan Authors

Immune thrombocytopenic purpura (ITP) is a rare hematologic condition through to affect 3.3 in 100,000 adults per year in the United States. Many cases of immune thrombocytopenia are diagnosed incidentally with laboratory tests that reveal low platelet count, without a clear cause. However, when platelet counts are very low, patients may show signs of bleeding. Here we present the case of a 24-year-old female with mucocutaneous bleeding ten days after receiving her first dose of SARS-CoV-2 vaccine, who was subsequently found to have severe thrombocytopenia. Extensive work up for new thrombocytopenia was unremarkable suggesting a diagnosis of ITP ...


Newer Horizon Of Mesenchymal Stem Cell-Based Therapy In The Management Of Sars-Cov-2-Associated Mucormycosis: A Safe Hope For Future Medicine, Alok Raghav, Syed Ghazanfar Ali, Goo-Bo Jeong, Kirti Amresh Gautam, Shahid Banday, Qazi Noorul Mateen, Prashant Tripathi, Richa Giri, Saurabh Agarwal, Manish Singh, Haris M. Khan 2021 Ganesh Shankar Vidyarthi Memorial Medical College

Newer Horizon Of Mesenchymal Stem Cell-Based Therapy In The Management Of Sars-Cov-2-Associated Mucormycosis: A Safe Hope For Future Medicine, Alok Raghav, Syed Ghazanfar Ali, Goo-Bo Jeong, Kirti Amresh Gautam, Shahid Banday, Qazi Noorul Mateen, Prashant Tripathi, Richa Giri, Saurabh Agarwal, Manish Singh, Haris M. Khan

COVID-19 Publications by UMass Chan Authors

SARS-CoV-2-infected patients are reported to show immunocompromised behavior that gives rise to a wide variety of complications due to impaired innate immune response, cytokine storm, and thrombo-inflammation. Prolonged use of steroids, diabetes mellitus, and diabetic ketoacidosis (DKA) are some of the factors responsible for the growth of Mucorales in such immunocompromised patients and, thus, can lead to a life-threatening condition referred to as mucormycosis. Therefore, an early diagnosis and cell-based management cosis is the need of the hour to help affected patients overcome this severe condition. In addition, extended exposure to antifungal drugs/therapeutics is found to initiate hormonal and ...


Neutralizing Antibody-Independent Immunity To Sars-Cov-2 In Hamsters And Hace-2 Transgenic Mice Immunized With A Rbd/Nucleocapsid Fusion Protein [Preprint], Julia T. Castro, Ricardo T. Gazzinelli 2021 University of Sao Paulo, Brazil

Neutralizing Antibody-Independent Immunity To Sars-Cov-2 In Hamsters And Hace-2 Transgenic Mice Immunized With A Rbd/Nucleocapsid Fusion Protein [Preprint], Julia T. Castro, Ricardo T. Gazzinelli

UMass Chan Medical School Faculty Publications

The nucleocapsid (N) and the receptor binding domain (RBD) of the Spike (S) proteins elicit robust antibody and T cell responses either in vaccinated or COVID-19 convalescent individuals. We generated a chimeric protein that comprises the sequences of RBD from S and N antigens (SpiN). SpiN was highly immunogenic and elicited a strong IFNγ response from T cells and high levels of antibodies to the inactivated virus, but no neutralizing antibodies. Importantly, hamsters and the human Angiotensin Convertase Enzyme-2-transgenic mice immunized with SpiN were highly resistant to challenge with the wild type SARS-CoV-2, as indicated by viral load, clinical outcome ...


Evolution Of Protection After Maternal Immunization For Respiratory Syncytial Virus In Cotton Rats [Preprint], Jorge C.G. Blanco, Lori McGinnes Cullen, Arash Kamali, Fatoumata Y. D. Sylla, Marina S. Boukhavalova, Trudy G. Morrison 2021 Sigmovir Biosystems, Inc

Evolution Of Protection After Maternal Immunization For Respiratory Syncytial Virus In Cotton Rats [Preprint], Jorge C.G. Blanco, Lori Mcginnes Cullen, Arash Kamali, Fatoumata Y. D. Sylla, Marina S. Boukhavalova, Trudy G. Morrison

UMass Chan Medical School Faculty Publications

Maternal anti-respiratory syncytial virus (RSV) antibodies acquired by the fetus through the placenta protect neonates from RSV disease through the first weeks of life. In the cotton rat model of RSV infections, we previously reported that immunization of dams during pregnancy with virus-like particles assembled with mutation stabilized pre-fusion F protein as well as the wild type G protein resulted in robust protection of their offspring from RSV challenge (Blanco, et al Journal of Virology 93: e00914-19, https://doi.org/10.1128/JVI.00914-19). Here we describe the durability of those protective responses in dams, the durability of protection in ...


High-Throughput Human Primary Cell-Based Airway Model For Evaluating Influenza, Coronavirus, Or Other Respiratory Viruses In Vitro, A. L. Gard, Ping Liu, Jennifer P. Wang, Robert W. Finberg, J. T. Borenstein 2021 Draper

High-Throughput Human Primary Cell-Based Airway Model For Evaluating Influenza, Coronavirus, Or Other Respiratory Viruses In Vitro, A. L. Gard, Ping Liu, Jennifer P. Wang, Robert W. Finberg, J. T. Borenstein

COVID-19 Publications by UMass Chan Authors

Influenza and other respiratory viruses present a significant threat to public health, national security, and the world economy, and can lead to the emergence of global pandemics such as from COVID-19. A barrier to the development of effective therapeutics is the absence of a robust and predictive preclinical model, with most studies relying on a combination of in vitro screening with immortalized cell lines and low-throughput animal models. Here, we integrate human primary airway epithelial cells into a custom-engineered 96-device platform (PREDICT96-ALI) in which tissues are cultured in an array of microchannel-based culture chambers at an air-liquid interface, in a ...


Lessons From A Local Effort To Screen For Sars-Cov-2, Noah J. Silverstein, Jeremy Luban 2021 University of Massachusetts Medical School

Lessons From A Local Effort To Screen For Sars-Cov-2, Noah J. Silverstein, Jeremy Luban

COVID-19 Publications by UMass Chan Authors

It is breathtaking to consider how the response to pandemic viral pathogens has been transformed over the past century by greater knowledge of fundamental biology and technological innovations including PCR and next-generation sequencing. In striking contrast to the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the pathogen responsible for the 1918 influenza pandemic was not identified until years after the outbreak. The definitive text in 1927 described influenza as “an epidemiologic conception” likely caused by the bacterium Haemophilus influenzae. Six decades later, HIV-1 was discovered within a few years of the first report of AIDS, although it took ...


Antibody-Based Ccr5 Blockade Protects Macaques From Mucosal Shiv Transmission, Xiao L. Chang, Diogo M. Magnani, Lishomwa C. Ndhlovu, Jonah B. Sacha 2021 Oregon Health & Science University

Antibody-Based Ccr5 Blockade Protects Macaques From Mucosal Shiv Transmission, Xiao L. Chang, Diogo M. Magnani, Lishomwa C. Ndhlovu, Jonah B. Sacha

Open Access Publications by UMass Chan Authors

In the absence of a prophylactic vaccine, the use of antiretroviral therapy (ART) as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition by uninfected individuals is a promising approach to slowing the epidemic, but its efficacy is hampered by incomplete patient adherence and ART-resistant variants. Here, we report that competitive inhibition of HIV Env-CCR5 binding via the CCR5-specific antibody Leronlimab protects rhesus macaques against infection following repeated intrarectal challenges of CCR5-tropic SHIVSF162P3. Injection of Leronlimab weekly at 10 mg/kg provides significant but partial protection, while biweekly 50 mg/kg provides complete protection from SHIV acquisition. Tissue biopsies from protected macaques ...


Interim Estimates Of Vaccine Effectiveness Of Pfizer-Biontech And Moderna Covid-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021, Tamara Pilishvili, John P. Haran, Vaccine Effectiveness Among Healthcare Personnel Study Team, Gregory A. Volturo 2021 CDC COVID-19 Response Team

Interim Estimates Of Vaccine Effectiveness Of Pfizer-Biontech And Moderna Covid-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021, Tamara Pilishvili, John P. Haran, Vaccine Effectiveness Among Healthcare Personnel Study Team, Gregory A. Volturo

COVID-19 Publications by UMass Chan Authors

Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting. A test-negative case-control study is underway to evaluate mRNA COVID-19 vaccine effectiveness (VE) against symptomatic illness among HCP ...


A Diamidobenzimidazole Sting Agonist Protects Against Sars-Cov-2 Infection, Fiachra Humphries, Liraz Shmuel-Galia, Zhaozhao Jiang, Ruth Wilson, Philip Landis, Sze-Ling Ng, Krishna M. Parsi, Rene Maehr, John Cruz, Angel Morales-Ramos, Joshi M. Ramanjulu, John Bertin, G. Scott Pesiridis, Katherine A. Fitzgerald 2021 University of Massachusetts Medical School

A Diamidobenzimidazole Sting Agonist Protects Against Sars-Cov-2 Infection, Fiachra Humphries, Liraz Shmuel-Galia, Zhaozhao Jiang, Ruth Wilson, Philip Landis, Sze-Ling Ng, Krishna M. Parsi, Rene Maehr, John Cruz, Angel Morales-Ramos, Joshi M. Ramanjulu, John Bertin, G. Scott Pesiridis, Katherine A. Fitzgerald

COVID-19 Publications by UMass Chan Authors

Coronaviruses are a family of RNA viruses that cause acute and chronic diseases of the upper and lower respiratory tract in humans and other animals. SARS-CoV-2 is a recently emerged coronavirus that has led to a global pandemic causing a severe respiratory disease known as COVID-19 with significant morbidity and mortality worldwide. The development of antiviral therapeutics are urgently needed while vaccine programs roll out worldwide. Here we describe a diamidobenzimidazole compound, diABZI-4, that activates STING and is highly effective in limiting SARS-CoV-2 replication in cells and animals. diABZI-4 inhibited SARS-CoV-2 replication in lung epithelial cells. Administration of diABZI-4 intranasally ...


Expanded Analysis Of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia In Hospitalized Us Adults, Raul Isturiz, Gregory A. Volturo 2021 Pfizer Inc

Expanded Analysis Of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia In Hospitalized Us Adults, Raul Isturiz, Gregory A. Volturo

UMass Chan Medical School Faculty Publications

BACKGROUND: Streptococcus pneumoniae is a causative agent of community-acquired pneumonia (CAP). The 13-valent pneumococcal conjugate vaccine (PCV13) has significantly decreased the burden of PCV13-serotype pneumococcal disease; however, disease due to nonvaccine serotypes remains substantial. A recent study documented the persistence of PCV13 serotypes among US adults hospitalized with radiographically confirmed CAP. The current analysis used a recently developed urinary antigen detection (UAD) assay (UAD2) to extend these results to additional serotypes included in an investigational PCV20 vaccine.

METHODS: This prospective study enrolled adults aged > /=18 years hospitalized with radiographically confirmed CAP between October 2013-September 2016. Presence of S pneumoniae was ...


Vectored Immunotherapeutics For Infectious Diseases: Can Raavs Be The Game Changers For Fighting Transmissible Pathogens?, Wei Zhan, Manish Muhuri, Phillip W. L. Tai, Guangping Gao 2021 University of Massachusetts Medical School

Vectored Immunotherapeutics For Infectious Diseases: Can Raavs Be The Game Changers For Fighting Transmissible Pathogens?, Wei Zhan, Manish Muhuri, Phillip W. L. Tai, Guangping Gao

Open Access Publications by UMass Chan Authors

Conventional vaccinations and immunotherapies have encountered major roadblocks in preventing infectious diseases like HIV, influenza, and malaria. These challenges are due to the high genomic variation and immunomodulatory mechanisms inherent to these diseases. Passive transfer of broadly neutralizing antibodies may offer partial protection, but these treatments require repeated dosing. Some recombinant viral vectors, such as those based on lentiviruses and adeno-associated viruses (AAVs), can confer long-term transgene expression in the host after a single dose. Particularly, recombinant (r)AAVs have emerged as favorable vectors, given their high in vivo transduction efficiency, proven clinical efficacy, and low immunogenicity profiles. Hence, rAAVs ...


Robust Igm Responses Following Vaccination Are Associated With Prevention Of Mycobacterium Tuberculosis Infection In Macaques [Preprint], Edward B. Irvine, Wenjun Li, Sarah Fortune, Galit Alter 2021 Harvard University

Robust Igm Responses Following Vaccination Are Associated With Prevention Of Mycobacterium Tuberculosis Infection In Macaques [Preprint], Edward B. Irvine, Wenjun Li, Sarah Fortune, Galit Alter

UMass Chan Medical School Faculty Publications

Development of an effective tuberculosis (TB) vaccine has suffered from an incomplete understanding of the correlates of protection against Mycobacterium tuberculosis (Mtb). However, recent work has shown that compared to standard intradermal Bacille Calmette-Guerin (BCG) vaccination, intravenous (IV) BCG vaccination provides nearly complete protection against TB in rhesus macaques. While studies have focused on cellular immunity in this setting, the antibody response elicited by IV BCG vaccination remains incompletely defined. Using an agnostic antibody profiling approach, here we show that IV BCG drives superior antibody responses in the plasma and the bronchoalveolar lavage fluid (BAL). While IV BCG immunization resulted ...


Sodium Pyruvate Ameliorates Influenza A Virus Infection In Vitro And In Vivo, Jessica M. Reel 2021 Missouri State University

Sodium Pyruvate Ameliorates Influenza A Virus Infection In Vitro And In Vivo, Jessica M. Reel

MSU Graduate Theses

Pyruvate is produced in duplicate at the end of glycolysis in addition to ATP and NADH. Pyruvate is the metabolite of choice in most cells, whether obtained exogenously or endogenously. Recently we found that the addition of pyruvate’s conjugate base, sodium pyruvate, to cell culture media dampened the immune response to influenza A virus (IAV) infection in cultured innate immune cells. Thus, I decided to investigate the mechanism and potential for treatment of IAV. In vitro using bone marrow derived macrophages that were infected with IAV we found that adding sodium pyruvate to the media decreased immune signaling pathways ...


Immune Response Of Gamma-Irradiated Inactivated Bivalent Polio Vaccine Prepared Plus Trehalose As A Protein Stabilizer In A Mouse Model, Maryam Mollaei Alamuti, Mehrdad Ravanshad, Farahnaz Motamedi-Sedeh, Arezoo Nabizadeh, Elham Ahmadi, Seyedeh Maedeh Hossieni 2021 Tarbiat Modares University

Immune Response Of Gamma-Irradiated Inactivated Bivalent Polio Vaccine Prepared Plus Trehalose As A Protein Stabilizer In A Mouse Model, Maryam Mollaei Alamuti, Mehrdad Ravanshad, Farahnaz Motamedi-Sedeh, Arezoo Nabizadeh, Elham Ahmadi, Seyedeh Maedeh Hossieni

Open Access Publications by UMass Chan Authors

INTRODUCTION: Poliovirus causes paralysis by infecting the nervous system. Currently, 2 types of polio vaccine are given in many countries in polio eradication program including inactivated polio vaccine (IPV) and oral polio vaccine (OPV). Because of OPV-related paralysis, OPV should be replaced by IPV.

METHODS: The aim of this study was to prepare the gamma-irradiated IPV and determine its effectiveness compared with the commercial vaccine (OPV) in the mouse model. The virus titration of OPV was determined and then inactivated by the appropriate dose of gamma radiation into an irradiated vaccine formula. The vaccine was inoculated in BALB/c mice ...


Structural Basis Of Blastomyces Endoglucanase-2 Adjuvancy In Anti-Fungal And -Viral Immunity, Lucas Dos Santos Dias, Christina L. Gomez, Charles A. Specht, Stuart M. Levitz, Marcel Wuthrich 2021 University of Wisconsin

Structural Basis Of Blastomyces Endoglucanase-2 Adjuvancy In Anti-Fungal And -Viral Immunity, Lucas Dos Santos Dias, Christina L. Gomez, Charles A. Specht, Stuart M. Levitz, Marcel Wuthrich

Open Access Publications by UMass Chan Authors

The development of safe subunit vaccines requires adjuvants that augment immunogenicity of non-replicating protein-based antigens. Current vaccines against infectious diseases preferentially induce protective antibodies driven by adjuvants such as alum. However, the contribution of antibody to host defense is limited for certain classes of infectious diseases such as fungi, whereas animal studies and clinical observations implicate cellular immunity as an essential component of the resolution of fungal pathogens. Here, we decipher the structural bases of a newly identified glycoprotein ligand of Dectin-2 with potent adjuvancy, Blastomyces endoglucanase-2 (Bl-Eng2). We also pinpoint the developmental steps of antigen-specific CD4+ and CD8+ T ...


Non-Neutralizing Antibodies May Contribute To Suppression Of Sivmac239 Viremia In Indian Rhesus Macaques, Nuria Pedreno-Lopez, Brandon C. Rosen, Walter J. Flores, Matthew J. Gorman, Thomas B. Voigt, Michael J. Ricciardi, Kristin Crosno, Kim L. Weisgrau, Christopher L. Parks, Jeffrey D. Lifson, Galit Alter, Eva G. Rakasz, Diogo Magnani, Mauricio A. Martins, David I. Watkins 2021 George Washington University

Non-Neutralizing Antibodies May Contribute To Suppression Of Sivmac239 Viremia In Indian Rhesus Macaques, Nuria Pedreno-Lopez, Brandon C. Rosen, Walter J. Flores, Matthew J. Gorman, Thomas B. Voigt, Michael J. Ricciardi, Kristin Crosno, Kim L. Weisgrau, Christopher L. Parks, Jeffrey D. Lifson, Galit Alter, Eva G. Rakasz, Diogo Magnani, Mauricio A. Martins, David I. Watkins

Open Access Publications by UMass Chan Authors

The antiviral properties of broadly neutralizing antibodies against HIV are well-documented but no vaccine is currently able to elicit protective titers of these responses in primates. While current vaccine modalities can readily induce non-neutralizing antibodies against simian immunodeficiency virus (SIV) and HIV, the ability of these responses to restrict lentivirus transmission and replication remains controversial. Here, we investigated the antiviral properties of non-neutralizing antibodies in a group of Indian rhesus macaques (RMs) that were vaccinated with vif, rev, tat, nef, and env, as part of a previous study conducted by our group. These animals manifested rapid and durable control of ...


Synthetic Dna Delivery Of An Optimized And Engineered Monoclonal Antibody Provides Rapid And Prolonged Protection Against Experimental Gonococcal Infection, Elizabeth M. Parzych, Sunita Gulati, Bo Zheng, Mamadou A. Bah, Sarah T. C. Elliott, Jacqueline D. Chu, Nancy Nowak, George W. Reed, Frank J. Beurskens, Janine Schuurman, Peter A. Rice, David B. Weiner, Sanjay Ram 2021 The Wistar Institute of Anatomy and Biology

Synthetic Dna Delivery Of An Optimized And Engineered Monoclonal Antibody Provides Rapid And Prolonged Protection Against Experimental Gonococcal Infection, Elizabeth M. Parzych, Sunita Gulati, Bo Zheng, Mamadou A. Bah, Sarah T. C. Elliott, Jacqueline D. Chu, Nancy Nowak, George W. Reed, Frank J. Beurskens, Janine Schuurman, Peter A. Rice, David B. Weiner, Sanjay Ram

Open Access Publications by UMass Chan Authors

Monoclonal antibody (MAb) 2C7 recognizes a lipooligosaccharide epitope expressed by most clinical Neisseria gonorrhoeae isolates and mediates complement-dependent bactericidal activity. We recently showed that a recombinant human IgG1 chimeric variant of MAb 2C7 containing an E430G Fc modification (2C7_E430G), which enhances complement activation, outperformed the parental MAb 2C7 (2C7_WT) in vivo Because natural infection with N. gonorrhoeae often does not elicit protective immunity and reinfections are common, approaches that prolong bacterial control in vivo are of great interest. Advances in DNA-based approaches have demonstrated the combined benefit of genetic engineering, formulation optimizations, and facilitated delivery via CELLECTRA-EP technology, which can ...


Vaccines For Human Fungal Diseases: Close But Still A Long Way To Go, Lorena V. N. Oliveira, Ruiying Wang, Charles A. Specht, Stuart M. Levitz 2021 University of Massachusetts Medical School

Vaccines For Human Fungal Diseases: Close But Still A Long Way To Go, Lorena V. N. Oliveira, Ruiying Wang, Charles A. Specht, Stuart M. Levitz

Open Access Publications by UMass Chan Authors

Despite the substantial global burden of human fungal infections, there are no approved fungal vaccines to protect at risk individuals. Here, we review the progress that has been made and the challenges that lie ahead in the quest towards efficacious fungal vaccines. In mouse studies, protection has been achieved with vaccines directed against fungal pathogens, including species of Candida, Cryptococcus, and Aspergillus, that most commonly cause life-threatening human disease. Encouraging results have been obtained with vaccines composed of live-attenuated and killed fungi, crude extracts, recombinant subunit formulations, and nucleic acid vaccines. Novel adjuvants that instruct the immune system to mount ...


Digital Commons powered by bepress